The Effect of CPAP on Lung Hyperinflation in Patients With OSA

The Effect of Continuous Positive Airway Pressure Therapy on Lung Hyperinflation in Patients With Obstructive Sleep Apnoea

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04084899

Enrollment

Registered

2019-09-10

Start date

2019-09-05

Completion date

2020-01-09

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

Obstructive Sleep Apnea, Continuous Positive Airway Pressure, Lung hyperinflation

Brief summary

Assessment of the lung hyperinflation by bodypletysmography in patients with obstructive sleep apnoea treated with continuous positive airway pressure therapy.

Detailed description

Rationale: Obstructive sleep apnoea (OSA) is characterized by repetitive closure of upper airways leading to apnoea (complete airflow cessation) or hypopnoea (airflow limitation \> 50% + blood oxygen desaturation \> 3% or airflow limitation \> 30% blood oxygen desaturation \> 4%). The prevalence of lung hyperinflations in sleep apnoea patients and effect of continuous positive airway pressure (CPAP) therapy is not known. Process: Subjects included in the study will be obstructive sleep apnoea (OSA) patients diagnosed by respiratory polysomnography performed in the Sleep Laboratory, Department of Respiratory Medicine, University Hospital Olomouc. Bodypletysmography will be performed in the time of OSA diagnosis and after 3 months of CPAP therapy. Data will be statistically evaluated after completion of the target number of subjects.

Interventions

DEVICEContinuous Positive Airway Pressure therapy

Standard treatment with continuous positive airway pressure

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Obstructive sleep apnoea syndrome indicated for CPAP therapy (Apnoea- Hypopnoea index ˃ 15)

Exclusion criteria

* \- Bilevel positive airway pressure therapy * Total lung capacity \< 80% lower limit of normal values * Obstructive ventilatory disorder * Change in body weight ˃ 10% * Change in smoking status

Design outcomes

Primary

Measure	Time frame	Description
Change of Vital Capacity (VC) (ml)	3 months	Percentage change of Vital Capacity after 3 months of CPAP therapy.
Change of Forced Expiratory Volume in 1 second (FEV1) (ml)	3 months	Percentage change of Forced Expiratory Volume in 1 second after 3 months of CPAP therapy.
Change of Total Lung Capacity (TLC) (ml)	3 months	Percentage change of Total Lung Capacity after 3 months of CPAP therapy.
Change of Residual Volume (RV) (ml)	3 months	Percentage change of Residual Volume after 3 months of CPAP therapy.

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026